Chronic Myelomonocytic Leukemia clinical trials at University of California Health

9 in progress, 4 open to eligible people

Showing trials for

  • A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML

    open to eligible people ages 18 years and up

    The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine or decitabine

    at UC Davis

  • A Study of IO-202 as Monotherapy in Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

    open to eligible people ages 18 years and up

    To assess safety and tolerability at increasing dose levels of IO-202 as monotherapy and in combination with Azacitidine in successive cohorts of participants with relapsed or refractory AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D) and dose schedule as monotherapy and combination therapy.

    at UC Davis UC Irvine UCSF

  • A Study of Oral LY3410738 in Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

    open to eligible people ages 18 years and up

    This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

    at UC Davis UCLA

  • Tagraxofusp (SL-401) in Patients With CMML or MF

    open to eligible people ages 18 years and up

    This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or myelofibrosis (MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive chemotherapy; and one enrolling treatment-naive patients with CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort will enroll patients who are resistant/refractory or intolerant to approved JAK therapy (JAK1/JAK2 or JAK2).

    at UCLA

  • A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

    Sorry, in progress, not accepting new patients

    This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.

    at UCSF

  • Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

    Sorry, in progress, not accepting new patients

    This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

    at UC Davis UC Irvine UCLA UCSD UCSF

  • Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    Sorry, in progress, not accepting new patients

    This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.

    at UC Davis

  • Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML).

    at UCSD

  • Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

    Sorry, in progress, not accepting new patients

    This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line setting and are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with IPSS-R intermediate, high, very high risk MDS and CMML-2.

    at UCLA

Our lead scientists for Chronic Myelomonocytic Leukemia research studies include .

Last updated: